Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025Current Opinion in Oncology

The role of menin inhibitors in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

AIAlessandro IsidoriGMGiovanni Marconi

Discussion

Loading...

Member takes

Overview

Recent trials show menin inhibitors improve remission rates in acute myeloid leukemia, suggesting new treatment options.

Key Points

  • Menin inhibitors demonstrate promising results in treating acute myeloid leukemia, particularly in relapsed cases.
  • Composite complete remission rates range from 23% to 48% with current menin inhibitors, indicating effectiveness in specific populations.
  • Observational trials combining menin inhibitors with venetoclax show overall response rates as high as 100%, highlighting unique treatment strategies.
  • Resistance mechanisms like MEN1 mutations pose challenges, yet combination therapies may enhance treatment outcomes for AML patients.

Cite This Study

Isidori et al. (2025) studied this question.

synapsesocial.com/papers/68af6bf77567bf4f94fe9692https://doi.org/10.1097/cco.0000000000001185
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review2025 · 7 citations
  2. 2Combination Strategies with Menin Inhibitors for Acute Leukemia2025 · 6 citations
  3. 3Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis2025
  4. 4The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival2025
  5. 5Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors2025